Cargando…

Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems

PURPOSE: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hengfeng, Gao, Yue, Lian, Chunfang, Zhang, Yun, Wang, Bangyuan, Yang, Yanfang, Ye, Jun, Feng, Yu, Liu, Yuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735633/
https://www.ncbi.nlm.nih.gov/pubmed/31564878
http://dx.doi.org/10.2147/IJN.S214883
_version_ 1783450383861940224
author Liao, Hengfeng
Gao, Yue
Lian, Chunfang
Zhang, Yun
Wang, Bangyuan
Yang, Yanfang
Ye, Jun
Feng, Yu
Liu, Yuling
author_facet Liao, Hengfeng
Gao, Yue
Lian, Chunfang
Zhang, Yun
Wang, Bangyuan
Yang, Yanfang
Ye, Jun
Feng, Yu
Liu, Yuling
author_sort Liao, Hengfeng
collection PubMed
description PURPOSE: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. METHODS: Two SMEDDS were characterized by emulsifying efficiency, droplet size, zeta potential, cloud point, dilution stability, physical stability, and in vitro release and lipolysis. Different formulations of 40 mg/kg baicalein were orally administered to Sprague-Dawley rats to investigate their respective bioavailabilities. The chylomicron flow blocking rat model was used to evaluate their lymphatic transport. RESULTS: The droplet sizes of BAPC-SMEDDS and CBA-SMEDDS after 100x dilution were 9.6±0.2 nm and 11.3±0.4 nm, respectively. In vivo experiments indicated that the relative bioavailability of CBA-SMEDDS and BAPC-SMEDDS was 342.5% and 448.7% compared to that of free baicalein (BA). The AUC(0–t) and C(max) of BAPC-SMEDDS were 1.31 and 1.87 times higher than those of CBA-SMEDDS, respectively. The lymphatic transport study revealed that 81.2% of orally absorbed BA entered the circulation directly through the portal vein, whereas approximately 18.8% was transported into the blood via lymphatic transport. CBA-SMEDDS and BAPC-SMEDDS increased the lymphatic transport ratio of BA from 18.8% to 56.2% and 70.2%, respectively. Therefore, self-microemulsion not only significantly improves oral bioavailability of baicalein, but also increases the proportion lymphatically transported. This is beneficial to the direct interaction of baicalein with relevant immune cells in the lymphatic system and for proper display of its effects. CONCLUSION: This study demonstrates the oral absorption and lymphatic transport characteristics of free baicalein and baicalein SMEDDS with different compositions. This is of great significance to studies on lymphatic targeted delivery of natural immunomodulatory compounds.
format Online
Article
Text
id pubmed-6735633
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67356332019-09-27 Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems Liao, Hengfeng Gao, Yue Lian, Chunfang Zhang, Yun Wang, Bangyuan Yang, Yanfang Ye, Jun Feng, Yu Liu, Yuling Int J Nanomedicine Original Research PURPOSE: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. METHODS: Two SMEDDS were characterized by emulsifying efficiency, droplet size, zeta potential, cloud point, dilution stability, physical stability, and in vitro release and lipolysis. Different formulations of 40 mg/kg baicalein were orally administered to Sprague-Dawley rats to investigate their respective bioavailabilities. The chylomicron flow blocking rat model was used to evaluate their lymphatic transport. RESULTS: The droplet sizes of BAPC-SMEDDS and CBA-SMEDDS after 100x dilution were 9.6±0.2 nm and 11.3±0.4 nm, respectively. In vivo experiments indicated that the relative bioavailability of CBA-SMEDDS and BAPC-SMEDDS was 342.5% and 448.7% compared to that of free baicalein (BA). The AUC(0–t) and C(max) of BAPC-SMEDDS were 1.31 and 1.87 times higher than those of CBA-SMEDDS, respectively. The lymphatic transport study revealed that 81.2% of orally absorbed BA entered the circulation directly through the portal vein, whereas approximately 18.8% was transported into the blood via lymphatic transport. CBA-SMEDDS and BAPC-SMEDDS increased the lymphatic transport ratio of BA from 18.8% to 56.2% and 70.2%, respectively. Therefore, self-microemulsion not only significantly improves oral bioavailability of baicalein, but also increases the proportion lymphatically transported. This is beneficial to the direct interaction of baicalein with relevant immune cells in the lymphatic system and for proper display of its effects. CONCLUSION: This study demonstrates the oral absorption and lymphatic transport characteristics of free baicalein and baicalein SMEDDS with different compositions. This is of great significance to studies on lymphatic targeted delivery of natural immunomodulatory compounds. Dove 2019-09-06 /pmc/articles/PMC6735633/ /pubmed/31564878 http://dx.doi.org/10.2147/IJN.S214883 Text en © 2019 Liao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liao, Hengfeng
Gao, Yue
Lian, Chunfang
Zhang, Yun
Wang, Bangyuan
Yang, Yanfang
Ye, Jun
Feng, Yu
Liu, Yuling
Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title_full Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title_fullStr Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title_full_unstemmed Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title_short Oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
title_sort oral absorption and lymphatic transport of baicalein following drug–phospholipid complex incorporation in self-microemulsifying drug delivery systems
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735633/
https://www.ncbi.nlm.nih.gov/pubmed/31564878
http://dx.doi.org/10.2147/IJN.S214883
work_keys_str_mv AT liaohengfeng oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT gaoyue oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT lianchunfang oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT zhangyun oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT wangbangyuan oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT yangyanfang oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT yejun oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT fengyu oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems
AT liuyuling oralabsorptionandlymphatictransportofbaicaleinfollowingdrugphospholipidcomplexincorporationinselfmicroemulsifyingdrugdeliverysystems